Recce Pharmaceuticals Achieves Key Milestones
Company Announcements

Recce Pharmaceuticals Achieves Key Milestones

Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.

Recce Pharmaceuticals Ltd. has reported significant milestones, including positive clinical trial results for its anti-infective agent RECCE 327, successful expansion of clinical trials, and inclusion on the WHO’s list of antibacterial products in development. Financially, the company secured a substantial pro-forma cash position of A$16 million after an institutional placement and a Share Purchase Plan aimed at raising approximately A$10 million. Additionally, they received a A$2.6 million R&D Tax Incentive rebate from the Australian Tax Office.

For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskRecce Pharmaceuticals Boosted by $6.75M R&D Rebate
TipRanks Australian Auto-Generated NewsdeskRecce Pharmaceuticals Issues New Options for Growth
TipRanks Australian Auto-Generated NewsdeskRecce Pharmaceuticals Advances Phase 3 Trial in Indonesia
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App